Abaloparatide vs HGH
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 55% Abaloparatide and HGH work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Abaloparatide HGH
Weight 3,960 Da 22,124 Da
Half-life ~1.7 hours 3-4 hours (SC), 20-30 minutes (IV)
Chain 34 amino acids 191 amino acids
Type Synthetic PTHrP analog Single-chain polypeptide with two disulfide bridges
Key Benefits
Abaloparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic mechanism)
03 Superior hip BMD gains vs teriparatide in trials
04 Reduces vertebral fracture risk significantly
05 Reduces nonvertebral fracture risk
06 Lower hypercalcemia risk than teriparatide
07 Works through selective PTH1R activation
08 Benefits seen within 6 months
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Abaloparatide
80 mcg / Once daily
Osteoporosis treatment 80 mcg Once daily
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Abaloparatide
Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo
Injection site reactions
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Abaloparatide HGH
Status Extensively Studied FDA Approved
References 4 studies 4 studies
Latest — 2024
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.